Amphista Therapeutics Expands Research Team by Appointing Martin O’Rourke as Head of Drug Discovery and James Osborne as Director of Chemistry   Glasgow, Scotland, 28 June 2021 – Amphista Therapeutics, a Targeted Protein Degradation (TPD) biopharmaceutical company creating first-in-class cancer therapeutics that harness the body’s natural processes to remove disease-causing proteins selectively and efficiently, today […]